Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADL NASDAQ:GLUE NASDAQ:RNAC NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$6.29-2.5%$5.74$3.79▼$14.60$315.13M-0.881.01 million shs592,013 shsGLUEMonte Rosa Therapeutics$4.79-3.2%$4.95$3.50▼$12.40$294.63M1.42468,839 shs578,534 shsRNACCartesian Therapeutics$12.33-3.7%$11.27$8.46▼$26.50$319.96M0.4475,532 shs77,855 shsVTGNVistaGen Therapeutics$2.92+1.7%$2.40$1.90▼$3.79$87.19M0.4506,276 shs329,032 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics0.00%-10.40%+23.33%+26.31%+16.27%GLUEMonte Rosa Therapeutics0.00%-15.52%-5.05%+3.46%+19.45%RNACCartesian Therapeutics0.00%-7.50%+10.34%-0.88%-14.38%VTGNVistaGen Therapeutics0.00%-5.19%+44.20%+24.26%-8.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics2.1731 of 5 stars3.62.00.00.01.41.70.6GLUEMonte Rosa Therapeutics1.2677 of 5 stars3.30.00.00.00.61.70.6RNACCartesian Therapeutics2.0245 of 5 stars3.40.00.00.03.03.30.0VTGNVistaGen Therapeutics1.0136 of 5 stars0.05.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.20Buy$22.00249.76% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33220.11% UpsideRNACCartesian Therapeutics 2.83Moderate Buy$40.00224.41% UpsideVTGNVistaGen Therapeutics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest VTGN, CADL, GLUE, and RNAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/9/2025RNACCartesian TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.006/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.006/18/2025VTGNVistaGen TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/8/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.00(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,626.08N/AN/A$1.41 per share4.46GLUEMonte Rosa Therapeutics$75.62M3.90N/AN/A$3.63 per share1.32RNACCartesian Therapeutics$38.91M8.22N/AN/A($0.27) per share-45.67VTGNVistaGen Therapeutics$490K177.94N/AN/A$2.44 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)GLUEMonte Rosa Therapeutics-$72.70M$0.0859.88N/AN/A3.86%2.65%1.65%8/14/2025 (Estimated)RNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/AN/AN/A-7.01%8/6/2025 (Estimated)VTGNVistaGen Therapeutics-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/7/2025 (Estimated)Latest VTGN, CADL, GLUE, and RNAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31N/AN/AN/A$7.23 millionN/A8/14/2025N/ARNACCartesian Therapeutics-$0.77N/AN/AN/A$0.77 millionN/A8/12/2025Q2 2025CADLCandel Therapeutics-$0.17N/AN/AN/AN/AN/A8/7/2025Q1 2026VTGNVistaGen Therapeutics-$0.46N/AN/AN/A$0.22 millionN/A6/17/2025Q4 2025VTGNVistaGen Therapeutics-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 million5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.014.644.64GLUEMonte Rosa TherapeuticsN/A5.615.61RNACCartesian TherapeuticsN/A12.3412.34VTGNVistaGen TherapeuticsN/A6.516.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%GLUEMonte Rosa Therapeutics79.96%RNACCartesian Therapeutics86.95%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%GLUEMonte Rosa Therapeutics6.50%RNACCartesian Therapeutics60.30%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.51 millionOptionableRNACCartesian Therapeutics6425.95 million10.30 millionOptionableVTGNVistaGen Therapeutics4029.86 million29.01 millionOptionableVTGN, CADL, GLUE, and RNAC HeadlinesRecent News About These CompaniesVistaGen Therapeutics (VTGN) to Release Earnings on ThursdayAugust 2 at 4:46 PM | marketbeat.comVistagen to Present at the BTIG Virtual Biotechnology ConferenceJuly 24, 2025 | businesswire.comVistaGen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50-Day Moving Average - Time to Sell?July 16, 2025 | marketbeat.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comStifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayJuly 3, 2025 | msn.comVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comVistagen Appoints Elissa Cote as Chief Corporate Development OfficerJune 25, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call TranscriptJune 22, 2025 | insidermonkey.comWilliam Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)June 20, 2025 | theglobeandmail.comVistagen Therapeutics’ Earnings Call Highlights Progress and ChallengesJune 19, 2025 | tipranks.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...June 18, 2025 | finance.yahoo.comVistagen Therapeutics Reports Progress in Clinical TrialsJune 17, 2025 | tipranks.comVistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comVistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | businesswire.comInsights into VistaGen Therapeutics's Upcoming EarningsJune 16, 2025 | benzinga.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look ForJune 16, 2025 | gurufocus.comVistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025June 12, 2025 | businesswire.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTGN, CADL, GLUE, and RNAC Company DescriptionsCandel Therapeutics NASDAQ:CADL$6.29 -0.16 (-2.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.28 0.00 (-0.08%) As of 08/1/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Monte Rosa Therapeutics NASDAQ:GLUE$4.79 -0.16 (-3.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.79 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$12.33 -0.48 (-3.75%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.32 -0.01 (-0.04%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.VistaGen Therapeutics NASDAQ:VTGN$2.92 +0.05 (+1.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.90 -0.02 (-0.68%) As of 08/1/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
